Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02610413 · ClinicalTrials.gov registry record
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
A clinical trial of Breast Carcinoma, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 354
- Enrollment target
- 1
- Study location
NCT02610413: Recruiting study of Breast Carcinoma, sponsored by National Cancer Institute (NCI).
NCT02610413 is a study of Breast Carcinoma that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 354 participants, below the 767-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02610413, a study of Breast Carcinoma, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 354 participants
- Enrollment target
- 1
- Study location
Study Summary
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.
Primary Outcome
Burden analysis will be used.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Massachusetts
- Eastern Cooperative Oncology Group - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2014-03-25 |
| Est. Completion | 2100-01-01 |
What NCT02610413 shows while recruiting
NCT02610413 is an observational study that tracks outcomes without assigning an intervention. The registered 354 participants enrollment target is mid-sized for trials with a published cap, below the 767-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT02610413 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02610413 about?
NCT02610413 is a clinical study titled "Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer". This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevac...
What is the current status of trial NCT02610413?
This trial is currently recruiting. The enrollment target is 354 participants. The study started on 2014-03-25. Estimated completion is 2100-01-01.
What conditions does trial NCT02610413 study?
This clinical trial studies the following conditions: Breast Carcinoma.
What interventions are being tested in trial NCT02610413?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02610413?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02610413 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02610413's enrollment target sits among peer trials
354 27th of 106 higher than 80 of 106 other Breast Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
RECRUITING
-
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02579967 · 354 participants · Phase 2
Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies
- NCT05729256 · 354 participants · NA
Alcohol and "Heat of the Moment" Sexual Decision Making
- NCT06507618 · 354 participants · Phase 3
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
- NCT07133308 · 355 participants · Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI